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Abstract: MicroRNAs (miRNAs) are small non-coding RNA molecules which function as critical
post-transcriptional gene regulators of various biological functions. Generally, miRNAs negatively
regulate gene expression by binding to their selective messenger RNAs (mRNAs), thereby leading to
either mRNA degradation or translational repression, depending on the degree of complementarity
with target mRNA sequences. Aberrant expression of these miRNAs has been linked etiologically
with various human diseases including breast cancer. Different cellular pathways of breast cancer
development such as cell proliferation, apoptotic response, metastasis, cancer recurrence and
chemoresistance are regulated by either the oncogenic miRNA (oncomiR) or tumor suppressor
miRNA (tsmiR). In this review, we highlight the current state of research into miRNA involved in
breast cancer, with particular attention to articles published between the years 2000 to 2019, using
detailed searches of the databases PubMed, Google Scholar, and Scopus. The post-transcriptional gene
regulatory roles of various dysregulated miRNAs in breast cancer and their potential as therapeutic
targets are also discussed.
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1. Introduction
MicroRNAs are a family of evolutionarily conserved small, endogenous, single-stranded and
non-protein coding RNAs spanning 19 to 25 nucleotides in length [1]. The first miRNA, lin-4,
was discovered in 1993 as a small RNA transcribed from the lin-4 locus of Caenorhabditis elegans [2].
According to the miRBase miRNA sequence database (release 22.0, March 2018) (http://www.mirbase.org/),
the human genome contains 2654 mature miRNA sequences to date [3]. miRNAs function as the key
post-transcriptional regulators of gene expression in different tissues and developmental stages via
highly specific interactions and complex regulatory networks [4].
The mechanisms of miRNA production or biogenesis involve several crucial biological steps
starting from miRNA transcription in the nucleus and with further processing and maturation in the
cytoplasm. miRNA genes can be intergenic or intragenic. Intergenic miRNA genes are independent,
with their own transcription units including promoters, transcript sequences. and terminator units [5,6].
However, intragenic genes are located either in the intronic or exonic regions of host genes, sharing the
same transcriptional units with these host genes [6,7]. Intronic miRNAs are found in the introns of
non-coding RNA or protein-coding genes, while the exonic miRNAs commonly overlap an exon and
an intron of a gene [8,9]. Mirtons are formed when the sequence of the introns of the host genes are
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identical to the precursor miRNA (pre-miRNA), with splice sites at either end [8,9]. Hence, Drosha
microprocessor processing is not essential for maturation of mirtons [10]. Drosha processing is the
process of generation of pre-miRNA from primary miRNA (pri-miRNA) in the first step of miRNA
biogenesis (Figure 1).
In mammals, miRNA genes are transcribed by RNA polymerase II/III to generate the primary
transcripts (pri-miRNAs). Pri-miRNAs typically comprise several thousand nucleotides in length
with local stem loop structures, a 5′-cap, and a poly-A tail [11,12]. RNA polymerase II is the major
polymerase type for transcription of miRNAs, though there are small groups of miRNAs associated with
Alu elements that are transcribed by RNA polymerase III [12,13]. As shown in Figure 1, pri-miRNAs
are then processed by a microprocessor complex, Drosha–DiGeorge syndrome critical region gene 8
(DGCR8), into the precursor transcripts (pre-miRNAs), which are approximately 70 nucleotides long
and in hairpin form [14,15]. Drosha is a RNase III-type endonuclease that cleaves the pri-miRNA,
while DGCR8 is a double-stranded RNA binding protein that acts as a molecular anchor recognizing
the pri-miRNA and ensuring correct splicing by Drosha [15].
Pre-miRNAs are then transported from the nucleus into the cytoplasm by RanGTP-dependent
nuclear transport reporter exportin 5 (XPO5) to undergo loop-cleavage by another RNase III enzyme
known as Dicer, with the aid of transactivation response RNA binding protein (TRBP) for generating an
approximately 20 nt-long mature miRNA/miRNA* duplex, as shown in Figure 1 [16–19]. The miRNA
duplexes are then incorporated into a member of the Argonaute (Ago) protein subfamily, facilitated
by the Dicer–TRBP complex and resulting in the formation of RNA-induced silencing complex
(RISC) [18,19]. The miRNA duplexes are separated or unwound into two single strands by RNA
helicases [20]. The guide strand (miRNA mature strand) remains bound to RISC, whereas the passenger
strand (miRNA*) undergoes degradation [18]. The Ago protein-bound mature miRNA is subsequently
assembled into an effector complex known as the miRNA-containing RNA-induced silencing complex
(miRISC) [18]. Within the miRISC, the mature miRNA then binds, with its ‘seed sequence’ (nucleotide
2 to 8 from miRNA 5′-end), to the 3′-UTR (and, in some cases, 5′-UTR and open reading frame (ORF))
of the target messenger RNA (mRNA) [21].
The degree of complementarity between the miRNAs and their mRNA targets determines the
inhibitory mechanism of protein expression. Perfect complementary between miRNAs and their mRNA
targets induces the degradation of the mRNA [22]. However, partial complementary base pairing
between miRNAs and their mRNA targets is more commonly observed, resulting in protein translational
repression or inhibition [22]. Due to their short miRNA–mRNA binding site, a single miRNA can bind
to multiple targeted mRNAs and regulate their functions in multiple pathways [23,24]. At the same
time, a single mRNA can be cooperatively targeted and bound by several different miRNAs [23,24]. It is
estimated that approximately one-third of protein-coding genes could be regulated by miRNAs [25].
Hence, the identification of validated targets of miRNAs is of great importance.
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Figure 1. MicroRNA biogenesis and modulation of miRNA activity. miRNA genes are transcribed to
produce primary miRNA transcripts (pri-miRNA) by RNA polymerase II. Drosha–DGCR8 complex
cleaves the pri-miRNA into a precursor miRNA transcript (pre-miRNA) which is then transported
from the nucleus into the cytoplasm via nuclear pore by exportin 5. In the cytoplasm, the pre-miRNA
is further modified by the DICER and TRBP complex to form a mature miRNA duplex. The miRNA
duplex is incorporated into an Argonaute (Ago) with RNA-induced silencing complex (RISC) and
the duplex is unwound by helicase into two single-stranded miRNAs. The mature single-stranded
miRNA can then bind to the target mRNA and exert its inhibitory function through translational block
or degradation of the mRNA depending on the level of nucleotide complementarity. Reproduced with
permission from Bhardwaj, A.; Singh, S.; Singh, A.P. MicroRNA-based cancer therapeutics: Big hope
from small RNAs. Mol. Cell Pharmacol. 2010 [26].
Owing to their diverse activity, miRNAs are able to regulate myriad cellular and signaling
pathways, including cell development and differentiation, cell proliferation, and apoptosis [27].
Dysregulation of a single miRNA or a small subset of miRNAs can therefore have significant
consequences in terms of cellular outcomes and, sometimes, the development of disease processes,
including cardiovascular diseases [28], neurodevelopmental diseases [29], autoimmune disorders [30],
bone diseases [31], and human cancers such as breast cancer [32,33]. Breast cancer is a complex disease
which poses a great challenge to human health, reduces life quality, and causes substantial financial
burden across the globe. According to the Global Cancer Project 2018 (GLOBOCAN 2018), female
breast cancer ranked as the second most commonly diagnosed cancer and the fifth leading cause of
cancer-related death worldwide. It was estimated that 2,088,849 newly identified breast cancer cases
(11.6% of 18.1 million new cases) and 626,679 breast cancer-related deaths (6.6% of 9.6 million deaths)
occurred globally in the year 2018, including both males and females [34]. Therefore, the prevalence and
lethality of breast cancer highlight the importance of investigating the mechanisms involved in breast
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tumorigenesis, as well as the development of new methods for its prognosis and the identification of
new therapeutic targets.
Breast cancer occurs due to abnormal proliferation of any cells or tissues lining the mammary
glands and ducts. Most of the breast malignant lesions are carcinomas which can be specifically
classified as adenocarcinomas [35]. Breast cancer is a highly heterogeneous disease with diverse
intertumoral and intratumoral non-uniformity, and with wide variation in tumors between affected
individuals [36]. Currently, breast cancer can also be classified into six molecular intrinsic subtypes:
luminal A, luminal B, HER+, normal-like, basal (also known as triple-negative), and claudin-low, each
based on their unique phenotype, tumor grade, and molecular characterizations including hormone
receptors and human EGF-like receptor 2 (HER2) receptor status [37]. Breast cancer is a complex
neoplastic disease, comprising the processes of tumor initiation and growth [38], metastasis and
invasion [39], and angiogenesis [40], with an additional significant possibility of relapse [41]. These
malignant changes occur when the cellular and molecular signaling pathways of the mammary cells
are disturbed or dysregulated [42].
The five-year survival rate of breast cancer at stage I, II, III, and IV are 100%, 93%, 72%, and 26%
respectively [43,44]. Although earlier diagnosis and detection of breast cancer has led to a decrease in
death rates, further advances in prevention, detection, and treatment are urgently required for the
improvement of breast cancer outcomes and survival [45]. Conventional breast cancer treatments,
such as surgery, radiation, chemotherapy, and hormone therapy, inevitably have side effects regarding
their post-treatment reaction or sensation, toxicities, and drug resistance, despite their undeniable
effectiveness in the treatment of early-stage breast cancer [46,47]. In recent years, miRNAs have
started to attract considerable interest for their regulatory involvement in the initiation, progression,
and metastasis of breast cancer [48]. Furthermore, the expression level of certain miRNAs is closely
linked to the morphological features, immunohistochemical profiles, histopathological parameters,
clinical outcomes, and prognosis and treatment responses of breast cancer [49]. In addition, studies
also revealed the presence of aberrant miRNA expression profiles in breast cancer conditions when
compared to their non-malignant counterparts [50]. As one of the largest classes of gene regulators,
miRNA molecules have vast potential as new biological therapeutic agents, targets, or biomarkers for
patient-tailored breast cancer treatment. This review considers the role of miRNAs associated with
breast cancer, explores their contributions to the etiology of the disease and discusses the prospects of
miRNA-based breast cancer therapeutic strategies.
2. Breast Cancer-Linked MicroRNAs
About 50% of the human miRNA-encoding genes are located in the cancer-linked regions or fragile
chromosomal sites [24]. Since the role of miRNA dysregulation in breast cancer was first reported
in 2005 [51], numerous studies have shown altered expression of miRNAs in breast cancer. These
breast cancer-associated miRNAs can be subdivided into the oncogenic miRNAs (oncomiRs) and tumor
suppressor miRNAs (tsmiRs), as discussed in the upcoming sections and summarized in Table 1.
OncomiRs are usually upregulated in breast cancer, suppressing the expression of potential tumor
suppressor genes and leading to breast malignancy [52]. Conversely, tsmiRs can inhibit the expression
of oncogenes that promote breast tumorigenesis [53]. Therefore, their downregulation can lead to
breast malignancy [52]. Figure 2 illustrates the specific regulatory action of oncomiRs and tsmiRs in
tumorigenic events.
Both oncomiRs and tsmiRs critically regulate breast tumor development and progression by
participating in complex regulatory networks [52]. These networks include several hallmarks of cancer,
such as sustaining growth and proliferative signals, replicative immortality, initiating metastasis and
invasion, resisting apoptotic and cell death responses, inducing angiogenesis, activating metabolism or
cellular energetics, and supporting cell immune escape [42,54].
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Figure 2. Regulatory mechanisms of oncogenic and tumor suppressor microRNAs in tumorigenic
events. Increased expression of oncogenic miRNAs in cancerous cells inhibits tumor suppressor genes.
Decreased expression of tumor suppressor miRNAs potentially enhances the expression of oncogenes.
Consequently, both oncogenic and tumor suppressor miRNAs lead to tumor development by stimulating
cell proliferation, anti-apoptotic response, replicative immortality, invasion, metastasis and angiogenesis.
Reproduced with permission from Joshi, M.; Singh Sodhi, K.; Pandey, R.; Singh, J.; Goyal, S.; Dahal, A.
MicroRNA: Biomarker for cancer diagnosis and prognosis. J. Pharm. Biomed. Sci. 2014 [55].
3. MicroRNAs and the Hallmarks of Breast Cancer
3.1 Cell Proliferation and Cell Cycle Regulation
Cell proliferation is the most important hallmark of breast cancer and its dysregulation is the
prime cause of breast tumorigenesis [42,54]. Cell cycle progression is essential in maintaining a delicate
balance between promoting cell prolife ation and its suppressio [56]. Healthy cells have a limited
capacity for cell division; th y have a finite number of c ll divisions that is in large determined by
reachi g an optimum cell density within a tissue. Once a finite cell density is reac ed, healthy cells will
desist from proliferation, arrest at the G0 phase of the cell cycle, and remain quiescent. This b havior of
non- ancerous cells is du to the response to the growth inhibitory influences from t environment [57].
This physiologically daptive cell cycle arrest mechanism is ab rrant in c ncer c lls [58]. Studies have
demonstrated that miRNAs hav a regulatory role in t e multiple cell proliferation and cell cycle
progression pathways of breast cancer, by functional interaction with factors su h as the cyclin protein
family, protein kinases nd their in ibitors, and other growt promoters or suppr ssors.
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The cyclin E1 gene has emerged as an important target for miRNAs that have decreased expression
in breast cancer, namely, the tsmiRs miR-497 [59], miR-16 [60], and miR-30c-2-3p [61]. Overexpression
of these tumor-suppressive miRNAs was able to inhibit breast cancer cell proliferation and cell cycle
progression. Cyclin E1 is an important cell cycle regulator of the G1–S transition [59–61]. For instance,
Huang and Lyu reported the downregulation of tumor suppressor miR-483-3p in breast cancer cells and
its overexpression significantly reduced cell proliferation and inhibited breast cancer G1–S cell cycle
transition. Cyclin E1 was shown to be a direct target of miR-483-3p. Decreased cyclin E1 expression by
miR-483-3p overexpression further prevents DNA synthesis initiation by p-NPAT, the downstream
target of cyclin E1, which blocks the breast cancer cells from entering the S-phase of the cell cycle.
Additionally, the formation of a complex between cyclin E1 and cyclin-dependent kinase CDK2,
responsible for cell cycle regulation, was also impeded upon miR-483-3p overexpression [62].
Aside from the increased expression of cyclins, the upregulation of protein kinases and
downregulation of its kinase inhibitors by miRNAs can also increase breast cancer cell viability
and result in aberration of the cell cycle transition. Zhou et al. reported that upregulation of
miR-143 by miRNA mimic suppressed the expression of extracellular signal-regulated kinase ERK5,
mitogen-activated protein kinase MAP3K7, and cyclin D1, which further reduced breast cancer
cell viability, while inhibition of miR-143 reversed these effects [63]. Wang et al. showed that
miR-455 overexpression could inhibit breast cancer cell proliferation by a double-knockdown effect
of Cdc2-related protein kinase CDK14 and cyclin D1 expression and also promoted expression of
tumor suppressor p21 [64]. It was also shown that forced expression of commonly downregulated
miR-424 in breast cancer cells enabled inhibition of cellular proliferation and regulation of the cell
cycle by arresting cells in the G2–M cell phase. This study also showed that miR-424 gained its
anti-oncogenic functions by binding to its selective target, cyclin-dependent kinase CDK1. In addition,
the expression of the Yes-associated protein YAP, of the Hippo pathway, and p-ERK1/2 of the ERK
pathway were also decreased upon miR-424 overexpression [65]. Furthermore, another study by
Chen et al. provided evidence that miR-543 suppressed breast cancer cell proliferation, hindered cell
cycling, and promoted cell apoptosis via direct regulating of ERK/MAPK pathway [66]. Huang et al.
revealed that the overexpression of miR-26a-5p with miRNA mimic transfection induced proliferative
growth of breast cancer cells, with a marked decreased in the expression levels of cell cycle regulators
cyclin D1, CDK4, and CDK6, and increased the expression of p21, p27, and p53 tumor suppressor
protein [67]. A subsequent study reported that the overexpression of miR-26a-5p also attenuated the
ring finger protein RNF6/ERα/BCL-xL axis [67].
Yan et al. showed that upon the induction of estradiol, the expression level of MYC increased,
resulting in transcriptional activation of a long non-coding RNA, PVT1, in breast cancer cells. Increased
levels of PVT1 also significantly induced the expression of miR-1207-5p in breast cancer samples
compared to non-cancerous controls. Increased miR-1207-5p expression promoted cell proliferation and
increased the percentage of cells at G2 phase of cell cycle, whereas miR-1207-5p inhibition suppressed
cell viability and cell cycle progression. Furthermore, overexpression of miR-1207-5p negatively
regulated STAT2 expression, and further inactivated cell cycle-dependent kinase inhibitors CDKN1A
and CDKN1B to promote cell cycle progression [68].
The markedly overexpressed miR-492 repressed the expression of transcription factor SOX7 in
both transcriptional and translational levels, resulting in increased cell proliferation and cell cycle
progression. As SOX7 is closely related to Wnt/β-catenin signaling activity, ectopic expression of
miR-492 also led to upregulation of cyclin D1 and c-MYC. Additionally, Shen et al. showed that
the percentage of cells at G0/G1 phase was decreased in miR-492-overexpressed breast cancer cells,
whereas the percentage cells at S phase was increased, suggesting that miR-492 promoted the G1–S cell
cycle transition [69].
Hua et al. stated that miR-135b was upregulated in breast cancer specimens and cell lines. Further
overexpression of miR-135b with miRNA mimic resulted in increased cell proliferation and accumulation
of S-phase and G2/M phase cells. This study also showed that miR-135b could promote cell growth
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and disrupt the cell cycle by negatively regulating LATS2 tumor suppressor kinase and the Hippo
pathway in breast cancer cells. In addition, genes downstream of LATS2 and Hippo pathways, including
cyclin-dependent kinase CDK2 and p-YAP, were also regulated under the miR-135b/LATS2 axis [70].
Dysregulation of miRNAs in cell proliferative and cell cycle regulatory pathways is also attributed
to resistance towards breast cancer treatments aimed at suppressing cell growth and proliferation [71].
Increased WBP2, which functions as the transcriptional coactivator of ERα/progesterone receptor
(PR) transactivation, was associated with poor prognosis in ER+ breast cancer patients. Increased
WBP2 expression also facilitated G1–S transition by regulating cell cycle-related proteins, including,
p21, CDK4, and cyclin D1. Moreover, miR-206 overexpression and WBP2 knockdown reduced
tamoxifen-resistance in breast cancer cells [72]. A study by Chu et al. also proved that suppressed
expression of miR-15a/16 caused tamoxifen resistance in breast cancer cells by increasing the cell
proliferation rate and cell cycle progression, while forced expression of miR-15a/16 re-sensitized breast
cancer cells towards tamoxifen treatment by negatively inhibiting cyclin E1. In addition, increased
expression of E2F7, which often correlated with higher relapse and poor prognosis in tamoxifen-treated
breast cancer patients, was found to inhibit transcription of the miR-15a/16 cluster. In summary of these
findings, overexpression of E2F7 resulted in decreased expression of the miR-15a/16 cluster, promoted
cyclin E1 expression, and further induced cell growth via tamoxifen resistance [73]. Additionally,
Liu et al. report the presence of a miR-26a/E2F7/MYC feedback loop in the regulation of tamoxifen
resistance in ER+ breast cancer.
miR-26a was downregulated in ER+ breast cancer tissues whereas transcription factor E2F7
was upregulated. miR-26a overexpression by mimic transfection directly repressed E2F7 expression
via translational inhibition, and indirectly inhibited MYC expression partly via E2F7 repression.
E2F7 overexpression led to decreased expression of miR-26a through MYC-triggered transcriptional
inhibition of miRNA. Resistance to tamoxifen was overcome with miR-26a overexpression and E2F7
silencing, which resulted in reduced breast cancer cell viability and G1 cell cycle arrest [74]. Studies by
Tormo et al. suggested that overexpression of miR-26a and miR-30b was responsible for sensitizing
HER+ breast cancer to trastuzumab treatment by inducing G1 arrest and decreasing the number of S
and G2 proliferative cells. The ability of miR-26a and miR-30b to induce sensitization to trastuzumab
treatment was shown to be via the effect of cyclin E2 silencing [75].
miR-365 [76] and miR-22 [77] also have decreased expression in breast cancer tissues relative
to healthy, non-tumor tissues. Forced expression of both miR-365 and miR-22 through miRNA
mimics gave rise to decreased breast cancer cell growth and increased sensitivity to fluorouracil and
paclitaxel, respectively. miR-365 and miR-22 gain their functions in overcoming chemoresistance
through respectively targeting GALNT4 and NRAS. GALNT4 is responsible for glycosylation-based
post-transcriptional protein modification, whereas NRAS is an oncogenic activator of PI3K/Akt-,
MAPK/ERK-, and NF-κB kinase-associated pathways; both are therefore important for cell proliferation
and tumor progression [76,77].
Glucocorticoid treatment is frequently used as a pretreatment co-medication in chemotherapy [78].
A study by Senthil Kumar et al. found that treatment with either the synthetic glucocorticoid
dexamethasone (DEX) or the natural glucocorticoid-mimicking compound, antcin A (ATA) markedly
increased miR-708 expression in breast cancer cells via glucocorticoid receptor alpha (GRα)
activation [79]. A decrease in the percentage of proliferative, viable breast cancer cells was observed
following treatment with either DEX, ATA, or transiently transfected precursor miR-708 compared
to the untreated controls, suggesting the inhibitory effects of DXE and ATA in breast tumorigenesis
are via the miR-708/GRα axis. In addition, treatment with DXE and ATA also resulted in cycle arrest
at the G2–M transition and G1–S transition phase, respectively. Further immunoblotting validation
confirmed that DEX and ATA downregulated the G1–S transition regulatory proteins, notably cyclin
D1, CDK4, and CDK6, whereas cyclin B and CDK1 were dramatically suppressed by ATA. However,
both the DEX and ATA treatment did not affect the protein expression levels of cyclin A and cyclin E.
Interestingly, upregulation of growth arrest regulatory proteins, p21Cip1 and p27Kip1, was also detected
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with either DEX or ATA treatment in breast cancer cells [79]. Furthermore, this study also showed that
the activation of miR-708 by DXE and ATA was able to impair IKKβ expression but not that of IKKα
nor IKKγ. The expression of the NF-κB-associated genes COX-2 and c-MYC was also decreased upon
miR-708 activation by GR agonist treatment or precursor miR-708 mimic transfection [79].
3.2. Metastasis and Invasion
Cancer cells have loose cell–matrix interactions in which they are less adhesive to the extracellular
matrix compared than non-cancerous cells, allowing them to invade or metastasize via surrounding
blood or lymphatic systems [80]. Epithelial–mesenchymal transition (EMT) is an important feature of
the breast cancer metastasis cascade, enabling cancer cells to acquire stem-like features and facilitating
their migratory and invasive capabilities [81]. EMT is known to involve loss of E-cadherin expression
which further reduces cell localization or cell–cell contact [82]. There are also studies indicating that
reduced levels of E-cadherin in cancer cells might potentiate the Wnt/β-catenin signaling pathway [83].
Overexpression of vimentin [84] and the expression switch of E-cadherin to N-cadherin is also a
promoter of EMT that contributes to cancer cells’ metastatic phenotype [85].
There is a growing body of literature supporting the role of microRNAs in influencing the
metastatic and invasive potential of breast cancer cells through the regulation of EMT and genes
responsible for cell motility and invasion. Jin et al. discovered that overexpression of the miR-200c/141
cluster mediated the metastatic potential of breast cancer cells by positively upregulating the expression
of SerpinB2. Overexpression of the miR-200c/141 cluster in breast cancer cells was also observed, with
elevated mRNA expression of various transcription factor members, including c-Jun, c-Fos, and FosB
mRNAs, nuclear import event of c-Jun, and induction of SerpinB2 promoter-directed chloramphenicol
acetyltransferase (CAT) activity. Additionally, the expression of miR-124a and miR-26b, which directly
targeted SepinB2, was downregulated in breast cancer cells. In a xenograft mouse model, miR-200c/141
overexpression promoted lung and lymph node metastasis, whereas siRNA-mediated SerpinB2
knockdown reverted the miR-200c/141-induced metastasis. SerpinB2 was highly associated with
metastasis risk in breast cancer by overexpression in the triple negative breast cancer subtype (TNBC)
compared to the luminal subtype. SerpinB2 was also correlated with increased metastatic potential
and unfavorable outcomes in breast cancer patients. Thus, this study suggested that high expression
of the miR-200c/141 cluster and SerpinB2 may serve as a prognostic indicator in TNBC cancer [86].
Other studies have found miRNAs that influence metastasis and cell invasion in breast cancer
with their activity being induced by FOXP3 and KAT2B. Zhang et al. found that both members
of the miR-200 family, miR-200c and miR-141, were induced by FOXP3, with KAT2B acting as the
coordinator. In this study, the heterozygous Foxp3 sf/+ breast cancer mouse model was used to analyze
the regulation of mouse miR-200s during tumor progression. miR-200c/141 expression was low in
tumor cells, but miR-200c/141was elevated in plasma during tumor progression and metastasis in
these mice. In breast cancer patients, it was also confirmed that the plasma levels of miR-200c/141
were higher in metastatic breast cancers compared to localized breast tumors. Additionally, in these
patients, the increased plasma miR-200c/141 appeared to originate from the tumor cells during cancer
progression, suggesting a potential role for this molecule as a biomarker for breast tumor metastasis [87].
Shao et al. demonstrated the elevated expression of plasma miR-200a and miR-210 in chemotherapy
resistance patients compared to chemosensitive patients. The expression of miR-200a was closely
associated with breast cancer stage, with increased expression of miR-210 in advanced stage IV
breast cancer. These authors also found that increased expression of miR-210 was correlated with
liver, lung, and brain internal organ metastasis. The association between miR-200 and miR-210
and chemoresistance suggest the potential for these molecules as biomarkers of drug resistance [88].
Other studies have verified that the expression profiles of circulating miRNAs extracted from plasma
were able to distinguish between breast cancer patients from localized luminal A group compared
to patients with metastatic breast cancer. This study showed the overexpression of miR-331 in
patients with metastatic breast cancer compared to patients with locally confined breast cancer or
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healthy controls. Contrastingly, underexpression of miR-195 was detected in breast cancer patients
with metastases in comparison to patients with localized breast cancer group or healthy controls.
Molecular studies confirmed the tumorigenic role of miR-331 is due to its association with gene targets
related to metastatic processes including HER2, HOTAIR, E2F1, DOHH, and PHLPP. In addition, the
role of miR-195, a known tumor suppressor, has also been validated by confirmation of its target
genes, FASN, HMGCR, ACACA, and CYP27B1, which are implicated in tumor growth, EMT, invasion,
and metastasis [89].
A study by Hong et al. also demonstrated the oncogenic properties of another member of the
miR-200 family, miR-200b. miR-200b was shown to enhance breast cancer cells’ invasion and migratory
ability via regulating Ezrin/Radixin/Moesin (ERM), a potential biomarker for breast tumor development.
These data suggest that the underlying metastatic mechanisms moderated by overexpression of miR-200
members could be different for different miRNAs. While there is clear potential for miRNAs of the
miR-200 family as biomarkers for breast cancer, further data are required to fully elucidate the
mechanisms through which these molecules contribute to the metastatic process and how they could
be advantageously used as biomarkers or treatment targets [90].
Rewiring of energy metabolism is widely regarded as a hallmark of breast cancer. It was
reported that miR-122 is highly secreted by breast cancer cells into the circulation. The high levels
of secreted miR-122 were attributed to reprogramming of glucose metabolism in the pre-metastatic
niche. In this study, miR-122 was shown to suppress glucose uptake by non-tumor cells in order to
accommodate the metabolic need of tumor cells. This process facilitated metastasis in vitro and in vivo,
due to the increased availability of nutrients in the pre-metastatic niche. Fong et al. identified that the
miR-122-induced decrease in glucose consumption in non-tumor cells was mediated by pyruvate kinase
(PKM) and citrate synthase (CS) downregulation. In vivo systemic administration of anti-miR-122
improved glucose uptake by distant organs, including the brain and lungs, and decreased the rate of
metastasis [91]. Wnt/β-catenin signaling has been demonstrated as one of the important regulators
controlling the mechanism of EMT and cancer metastasis. Cai et al. reported that miR-374a expression
was elevated in metastatic breast cancer cells and linked to a pro-metastatic phenotype in vitro.
A spindle- or star-like cell morphology was observed in miR-374a-enriched breast cancer cell cultures.
Additionally, aberrant expression of miR-374a was associated with substantial downregulation of
epithelial markers, including E-cadherin, γ-catenin, and CK18, whereas the expression of mesenchymal
markers, such as vimentin and N-cadherin, was significantly upregulated. These results suggested that
miR-374a was associated with EMT features in breast cancer cells. Ectopic expression of miR-374a also
enhanced distant metastasis in vivo. Studies indicated that miR-374a activated Wnt/β-catenin signaling
cascades as its overexpression resulted in enhanced β-catenin nuclear translocation. In addition,
miR-374a directly targeted and suppressed multiple negative regulators of the Wnt/β-catenin signaling
pathway, including WIF1, PTEN, and WNT5A [92].
Contrastingly, Jiang et al. found that miR-148a was downregulated in breast cancer cells
and tissues, and its overexpression by miRNA mimic decreased migration and invasion in breast
cancer cells. WNT-1, which is one of the ligands in Wnt/β-catenin signaling, was identified as
the target of miR-148a. In addition to the reduction of WNT-1 mRNA and protein levels, miR-148a
overexpression also decreased expression of the other critical components of the Wnt/β-catenin pathway,
including β-catenin, MMP-7, and TCF-4 in breast cancer cells. Additionally, miR-340 is another tumor
suppressor miRNA that may inhibit the migration, invasion, and metastasis of breast cancer cells by
targeting the Wnt/β-catenin signaling cascade [93]. Mohammadi-Yeganeh et al. identified miR-340
as functioning as a Wnt/β-catenin regulator miRNA by potentially targeting c-MYC and CTNNB1
(encoding β-catenin) in Wnt/β-catenin-dependent and ROCK1 in Wnt/β-catenin-independent signaling
pathways (Rho/Rho-associated kinase (ROCK) signaling pathway). These studies show that specific
miRNAs function as pivotal regulators in Wnt/β-catenin signaling pathway and therefore provide new
insights into the molecular mechanisms of breast cancer metastasis [94].
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The expression of miR-34a was downregulated in breast cancer specimens with lymph node
metastasis and breast cancer cell lines, with further decreased expression in advanced clinical stages.
Li et al. demonstrated that the expression level of miR-34a was inversely proportional to its direct
target TPD52, a well-recognized oncogene in breast cancer. Knockdown of TPD52 by miRNA mimic in
breast cancer cells increased E-cadherin expression levels while decreasing TGF-β and N-cadherin
levels. In addition, repression of EMT and restrained breast cancer cell migration and invasion were
observed following TPD52 targeting by miR-34a. Furthermore, decreased miR-138 was associated
with lymph node metastasis and invasion, whereas its overexpression led to inhibition of metastasis
in breast cancer cells [95]. Zhang et al. carried out further studies on miR-138 in breast cancer cells,
and found that miR-138 overexpression was involved in EMT inhibitory events via the impairment of
vimentin, N-cadherin, and Snail expression, but with activation of E-cadherin expression [96].
Tissue from infiltrating ductal breast carcinoma displayed significantly weak expression of miR-494
relative to the strong positive miR-494 expression that was observed in normal, healthy breast tissue.
Furthermore, elevated expression of miR-494 was strongly associated with increased expression of the
epithelial marker, E-cadherin, which acts an important regulator of EMT and metastasis. Zhan et al.
also showed that overexpression of miR-494 suppressed clonogenic and metastatic ability in vitro.
Additionally, ectopic expression of miR-494 inhibited neoplasm initiation as well as pulmonary
metastasis in vivo. Invasion of tumors into the peritoneal adipose tissue, abdominal muscle tissue,
and lung metastasis was also extensively decreased in nude mice with miR-494 overexpression
compared to the negative control. Further studies have determined that miR-494 gained its function by
inhibiting PAK1, and restoration of PAK1 expression was able to partially rescue miR-494 mediated
inhibition of malignant propagation [97].
miR-33b was identified as a negative regulator of cell stemness and metastasis in breast cancer. In
breast cancer cells, miR-33b was downregulated, and its expression negatively correlated with lymph
node metastasis status in breast cancer patients. Ectopic overexpression of miR-33b in highly metastatic
breast cancer cells inhibited cell stem-cell like properties, migration, and invasion in vitro, and
suppressed lung metastasis in vivo. Conversely, miR-33b knockdown resulted in the opposite effects.
Lin et al. showed that the mechanism of miR-33b-mediated inhibition of stemness or self-renewal,
migration, and invasion of breast cancer cells was through the negative regulation of its downstream
targets HMGA2, SALL4, and Twist1 [98]. In addition, there are numerous other miRNAs that appear to
be involved in the suppression of metastasis and invasion of breast cancer in vitro and in vivo; these
include the miRNAs miR-497, miR-421, miR-193a, miR-211-5p, miR-335, miR-133a, and miR-124, which
are proposed to suppress the expression of SMAD7, MTA1, WT1, SETBP1, EphA4, LASP1, and STAT3,
respectively [99–105]. These miRNAs were downregulated in breast cancer tissues. Furthermore,
re-introduction of the target genes reversed the inhibitory effects of these miRNAs on cell migration and
invasion. In addition to its inhibition of SMAD7 expression, a recent study also showed that miR-497,
together with miR-195, was able to directly target the 3′-UTR of cluster of differentiation CD274 (or
known as PD-L1) in TNBC cells, thus suggesting the potential of miR-497/195 in inhibiting the immune
response and tumor immune escape [106,107]. Previous studies have also shown high accordance
between CD274 expression and breast cancer metastases [107]. Additionally, Hong and team reported
the downregulation of miR-204-5p in breast cancer cells. The overexpression of miR-204-5p resulted in
a significant reduction in cell proliferation and migration in vitro, and inhibition of tumor growth and
metastatic events in vivo. Subsequent studies on molecular mechanisms revealed that miR-204-5p
is an important regulator of the PI3K/Akt signaling pathway by directly inhibiting PIK3CB, and its
overexpression led to improved sensitivity towards PIK3CB inhibitors and chemotherapeutic drugs
such as doxorubicin, taxanes, and bortezomib. Overexpression of miR-204-5p was also involved in
tumor immune microenvironment remodeling or reprogramming by regulating key genes related
to immune pathways, including TNF and cytokine signaling. In addition, a significant reduction
was observed in the number of various immune cells in the tumor microenvironment, including
myeloid-derived suppressor cells (MDSCs), macrophages, and natural killer (NK) cells as a result of
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miR-240-5p upregulation. By contrast, the overexpression of miR-240-5p resulted in an increase in the
number of CD4+ T cells, CD8+ T cells, and regulatory T cells [108]. In summary, it is important that
further research focuses on identifying the common metastasis and immune reprogramming regulatory
pathways that mediate the crosstalk between these miRNAs and their candidate target genes in order
to develop future prognostic and therapeutic strategies for anti-metastatic breast cancer treatment.
3.3. Apoptotic Response and Cell Death
Disruption to the chromosomal or genetic contents of a normal cell can lead to the induction of
a signaling pathway of programmed cell death, known as apoptosis, and which serves as a defense
mechanism [109]. Cancer cells are resistant to the apoptotic response even though their genetic contents
are profoundly affected [110]. Disruption to any given point of the apoptosis pathway can trigger
malignant transformation in mammary cells, enhancing cell viability [111]. It is shown that breast
cancer cells are able to evade the apoptotic response through a number of mechanisms, including loss
of tumor suppressor p53, dysregulation of caspase activity, upregulation of pro-survival regulators,
downregulation of pro-apoptotic factors, and deactivation of death ligands [111]. Recent research has
also shown that miRNAs play a significant role in the complex apoptotic regulatory mechanisms in
breast cancer by targeting or initiating components involved in multiple cell death pathways [112].
Breunig et al. found that increased oncogenic miR-519a-3p expression in breast cancer cells
enabled protection against the apoptosis-induced stimuli by TRAIL and Fas ligand, via diminishing
the expression of its target genes coding for TRAIL-R2 (TNFRSF10B) and caspase-8 and its indirect
target gene for caspase-7. miR-519a-3p also compromised the anti-tumor functionality of natural killer
(NK) cells by reducing granzyme B-induced apoptosis and negatively downregulating the expression
of two key ligands for the NK cell-activating receptor NKG2D, MICA and ULBP2. The latter process
enables cancer cells to avoid NK cell-mediated immune destruction by diminishing the recognition of
MICA and ULBP2 on the cell surface by NK cells. Furthermore, miR-519a-3p was highly expressed in
advanced-grade breast cancer with mutated p53 and associated with poor patient survival [113].
Sharma et al. found that the pro-apoptotic tumor suppressor p53 transcriptionally downregulated
the expression of miR-191-5p through binding to the p53 response element present in its promoter
region. In breast cancer cells, the overexpression of miR-191-5p resulted in a lower number of apoptotic
bodies and a decrease in caspase-3/-7 activity, whereas anti-miR-191-5p reverted this effect. Moreover,
the increased level of miR-191-5p was able to downregulate its potential target SOX4, which further
reduced the expression of p53 in breast cancer cells, indicating the existence of a p53-miR-191-SOX4
regulatory feedback loop. Additionally, it was found that anti-miR-191-5p treatment sensitized breast
cancer cells towards apoptosis induced by the drug doxorubicin by increasing p53, suggesting the
clinical potential of breast cancer therapeutics targeting this miRNA [114]. Wang et al. found that
overexpression of miR-204 by miRNA mimic also promoted apoptosis in breast cancer cells by directly
targeting JAK2. In addition, the expression level of miR-204 negatively correlated with p-STAT3 and
its downstream anti-apoptotic proteins BCL-2 and survivin in breast cancer [115]. miR-148a is also
associated with apoptosis, and is downregulated in breast cancer cells and tissues. Overexpression
of miR-148a reduced the viability and chemoresistance of breast cancer cells and enhanced the
apoptosis rate. Additionally, increased expression of miR-148a also prohibited tumor growth in vivo.
The restoration of miR-148a was also found to suppress its direct target BCL-2. BCL-2 is responsible
for preventing the release of mitochondrial apoptogenic factors into the cytoplasm, which further
deactivates caspases, leading to induction of a pro-survival response. This suggests that miR-148a may
serve as a potential tumor suppressor in breast cancer by silencing pro-survival BCL-2 [116].
Guan et al. report that miR-101 was downregulated in breast cancer cells and tissues, and
transfection of miR-101 mimic resulted in a marked increase in apoptosis. A decrease in EYA1
expression was also observed following miR-101 mimic transfection, and transfection of miR-101
inhibitor gave the opposite result. In addition, expression of the components of Notch signaling
pathways, including jagged1, Hes1, and Hey1 were significantly decreased following transfection with
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miR-101 mimic and EYA1-siRNA. Together, these findings suggest that miR-101 promotes apoptosis by
negatively targeting EYA1 via Notch signaling pathways [117]. Other research suggests that miR-101
overexpression induces apoptosis in breast cancer in vitro and in vivo by targeting SOX2. In addition
to the apoptotic response, suppression of SOX2 by miR-101 also resulted in inhibition of breast cancer
growth, proliferation, and migration [118].
Another group of Chinese researchers discovered that kallistatin, an endogenous protein, was able
to reduce viability and increase apoptotic cell death and caspase-3 activity in breast cancer cells.
Kallistatin was also found to induce autophagy in breast cancer cells by increased expression of
autophagy markers LC3B, Atg5, and beclin-1. Via its heparin-binding site, kallistatin can prompt
autophagy by antagonizing Wnt3a-induced cancer cell proliferation and increasing PPARγ expression
in breast cancer cells. Li et al. noted that kallistatin was able to inhibit the expression of oncogenic
miR-21 by inhibiting the miR-21–Akt pathway, leading to reduced expression of anti-apoptotic
BCL-2 and increased synthesis of pro-apoptotic BAX. Additionally, kallistatin reduced oncogenic
miR-203 expression via PKC-ERK activation, with increased expression of tumor suppressor SOCS3.
Conversely, the expression of the tumorigenic suppressors miR-34a and p53 was stimulated by
kallistatin. These findings therefore suggest that kallistatin has contrasting effects in breast cancer
cell death by suppressing the expression levels of miR-21 and miR-203, and stimulating miR-34a
synthesis [119].
In mammals, the telomere consists of TTAGGG tandem repeats that are localized at the end of each
chromosome and which serve to protect the chromosome against DNA damage and to prevent contact
with neighboring chromosomes [120]. The length of telomeres progressively shortens during the course
of cell division in human somatic cells, which finally leads to telomere dysfunction, chromosome
instability, and the initiation of cellular senescence, apoptosis, and human aging [121]. Cancer cells have
immortality due to their unique telomerase activity [121]. Telomerase is a ribonucleoprotein enzyme
complex which maintains and replenishes the telomeric DNA repeats at the chromosomal end—one
of the major tumor-promoting mechanisms in cancer [121]. The reverse transcriptase telomerase
protein (hTERT) and the telomerase RNA template (hTERC) are essential regulators of telomerase
activity [122]. A study by Dinami et al. showed that the expression of miR-296-5p and miR-512-5p,
both of which target hTERT, was downregulated in breast cancer cells. Low miR-296-5p/512-5p
expression and high hTERT expression are associated with poor clinical outcomes in basal-type breast
cancer patients. Ectopic expression of miR-296-5p/512-5p was attributed to lower telomerase activity,
weaker telomere maintenance, and the activation of replicative senescence and apoptosis programs
in basal breast cancer cells, whereas epigenetic silencing of miR-296-5p/512-5p mediated the hTERT
dependent proto-oncogenic effects of apoptosis protection in breast cancer cells [123]. The same group
of researchers previously showed that miR-155 was also upregulated in breast cancer cells. miR-155
expression was shown to reduce the expression of its direct target TRF1 at the telomeres [124]. TRF1
is one of the subunits of shelterin, also known as telosome, which is responsible for protection of
the telomere [125]. Elevated expression of miR-155 also resulted in telomere fragility and genomic
instability via inhibition of TRF1, and these are associated with poor clinical outcomes in ER+ breast
cancer [124].
3.4. Hypoxia and Angiogenesis
As a tumor develops, it rapidly expands beyond the existing vasculature and leads to the formation
of a tumor microenvironment of lower oxygen concentration compared to healthy tissues. This condition
is known as hypoxia, which acts as a key regulator of angiogenesis in breast cancer [126]. It is thought
that the sustained proliferation and growth of the breast tumor triggers neoangiogenesis, the formation
of new blood vessels, in order to supply oxygen and nutrients to the tumor [127]. At the same time,
the newly formed blood capillaries propagate the metastatic process by allowing easy penetration and
infiltration of cancer cells [128]. HIF is a family of hypoxia-inducible transcription factors that regulates
various critical breast cancer pathological processes, including stem cell homeostasis, cell proliferation,
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metastasis, and therapeutic resistance [129]. Additionally, VEGF is another important pro-angiogenic
factor that stimulates the buildup of blood vessels by endothelial cells [130]. Hence, knowledge of
the regulatory mechanisms of these hypoxia/angiogenesis-related genes by miRNAs could inform the
development of promising anti-angiogenic agents for breast cancer.
miR-210 is the most consistently and significantly induced miRNA during hypoxia. Camps et al.
performed a hypoxia timecourse miRNA sequencing data analysis on breast cancer cells.
The upregulation of miR-210-3p was detected throughout the whole timecourse of the study.
Additionally, upregulation of miR-210-3p was shown to be associated with HIF binding sites by HIF-1α
and HIF-2α chromatin immunoprecipitation (ChIP)-sequence analysis [131]. Zhang et al. also reported
that HIF-1αmRNA and miR-210 expression were markedly upregulated in a hypoxic environment [132].
Recent research by Costales et al. introduced a small molecule named Targapremir-210 that has binding
affinity to the Dicer site of the miR-210 hairpin precursor. This interaction inhibited the processing of
mature miR-210; reverted the repression of GPD1L, a hypoxia-associated protein negatively regulated
by miR-210; reduced HIF-1α levels; and triggered the apoptotic response in TNBC cells under hypoxic
conditions. Furthermore, Targapremir-210 also inhibited tumor growth in a hypoxic TNBC cancer
mouse xenograft model [133]. Additionally, Harquail et al. observed elevated expression of miR-210 in
breast cancer cells under hypoxic conditions. A concomitant decrease was also observed for Pax-5,
a protein target of miR-210 which is an important regulator of EMT/MET transitioning [134].
Nagpal et al. reported that the direct target of HIF-inducible miR-191 under hypoxia is the
mRNA coding for RNA binding protein, HuR. TGFβ-signaling pathways were stimulated as a
consequence of miR-191 negatively regulating HuR expression. The levels of several TGFβ pathway
genes, including TGFβ2, SMAD3, BMP4, JUN, FOS, PTGS2, CTGF, and VEGFA, were found to be higher
in miR-191-overexpressing breast cancer cells. Finally, miR-191-inhibiting treatment led to drastic
reduction in spheroid tumor volume [135].
Roscigno et al. noted an upregulation of miR-24 in breast cancer cells treated under hypoxic
conditions. Overexpression of miR-24 in these cells led to increased formation of mammospheres,
increased expression of Nanog and Oct-3/4 stemness genes, and decreased expression of pro-apoptotic
BimL. miR-24 was able to bind to its potential target F1H1, which encoded an asparaginylβ-hydroxylase
that promotes transcriptional repression of HIFs. Therefore, F1H1 suppression, as mediated by miR-24,
enabled HIF-1α protein stabilization and increased the levels of two HIF-1α direct targets, Snail and
VEGFA. Contrastingly, overexpression of F1H1 reverted these miR-24-mediated effects [136].
Li et al. discovered that overexpression of miR-29b could hinder Human Umbilical Vein Endothelial
Cells (HUVECs) formed by 3D capillary-like tubular structures, and tumor cell proliferation, migration,
and formation. The systemic treatment of miR-29b suppressed tumor vascularization, inhibited
infiltration of tumor-associated macrophages, inhibited tumor growth, and promoted the apoptotic
response in vivo, without inducing cytotoxicity. It was also demonstrated that the role of miR-29b
in anti-angiogenesis and anti-tumorigenesis was through functional targeting of Akt3 protein and
inducing VEGF and c-MYC arrest in breast cancer cells [137].
Furthermore, Wu et al. demonstrated downregulation of miR-497 expression in breast cancer cell
lines and clinical specimens. Overexpression of miR-497 by miR-497 mimic suppressed angiogenesis
in vitro and in a nude mouse model by regulating VEGF and HIF-1α. miR-497 overexpression in vitro
also disrupted the formation of capillary structures and led to a reduction in microvascular density
(MVD) in vivo [138].
Lu et al. found that miR-140-5p was downregulated in advanced clinical stage and metastatic
cancer tissues and associated with poorer prognosis. Overexpression of miR-140-5p by miRNA mimic
resulted reduced the aggressiveness of breast cancers and also reduced angiogenesis in vitro and
in vivo. The proposed mechanism for this effect was through targeted inhibition of VEGFA expression,
together with decreased expression of other proteins, including CD31, Ki-67, and MMP-9 [139]. There
is also evidence that miR-126 negatively regulates the pro-angiogenic protein VEGFA [140].
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Recent research has demonstrated that mesenchymal stem cells (MSCs) can be recruited to the
tumor microenvironment and promote tumor development through their interaction with tumor
cells [141]. A growing body of evidence suggests that the regulation of tumor stroma by MSCs is
via the secretion of extracellular vesicles such as exosomes [142]. MSC-derived exosomes have a key
function in cell-to-cell communication by transferring their components, which include miRNAs [142].
Pakravan et al. found that the shuttling of miR-100, which is enriched in MSC-derived exosomes,
was responsible for a significant downregulation in the expression and secretion of VEGF through
modulation of the mTOR/HIF-1α signaling axis in breast cancer cells. Additionally, the inhibitory
effects of MSC-derived exosomes on VEGF expression could be rescued with anti-miR-100 transfection,
further supporting the role of exosomal shuttling of miR-100 in breast cancer. Furthermore, depletion
of VEGF as mediated by MSC-derived exosomes was found to reduce the angiogenic behavior of
endothelial cells in vitro by decreasing cell proliferation and migration and capillary tube formation.
It therefore seems that exosomal miR-100 may serve as a potential angiogenic suppressor within the
microenvironment of breast cancer cells [143].
Table 1. MicroRNAs involved in the regulation of breast cancer.
MicroRNA Interacted/Correlated Gene(s) and Protein(s) Associated Events Reference
Major oncogenic microRNAs in breast cancer
miR-1207-5p STAT2, CDKN1A, CDKN1B Promotion of cell proliferation and G2 cell cycleprogression [68]
miR-492 SOX7, cyclin D1, c-MYC Promotion of cell proliferation and G1–S cellcycle progression [69]
miR-135b LATS2, CDK2, p-YAP Promotion of cell proliferation and S–G2/M cellcycle progression [70]
miR-200c and
miR-141 SerpinB2, c-Jun, c-Fos, FosB, FOXP3, KAT2B
Promote metastasis and elevated in serum of
metastatic mouse model and breast cancer
patients
[86,87]
miR-331 HER2, HOTAIR, E2F1, DOHH, PHLPP
Promotion of metastasis and invasion by
elevation in plasma of metastatic breast cancer
patients
[89]
miR-200b Ezrin/Radixin/Moesin (ERM) Promotion of metastasis and invasion [90]
miR-122 pyruvate kinase (PK) and citrate synthase (CS) Promotion of metastasis by reprogrammedglucose metabolism [91]
miR-374a E-cadherin, γ-catenin, CK18, vimentin,N-cadherin, B-catenin, WIF1, PTEN, WNT5A
Promotion of metastasis by regulating EMT and
Wnt/β-catenin signaling [92]
miR-519a-3p TRAIL-R2 (TNFRSF10B), caspase-8, caspase-7,MICA, ULBP2
Promotion of apoptosis resistance and escape
from natural killer cell recognition [113]
miR-191-5p SOX4, caspase-3, caspase-7, p53 Promotion of apoptosis resistance anddoxorubicin resistance [114]
miR-21 Akt, BCL-2, BAX Pro-survival effect can be overcome by kallistatin [119]
miR-203 PKC-ERK, SOCS3 Pro-survival effect can be overcome by kallistatin [119]
miR-155 TRF1 Telomere fragility and genomic instability [124]
miR-210 HIFs, GPD1L, Pax-5 Hypoxia-inducible miRNA [131–133]
miR-191 HuR, TGFβ2, SMAD3, BMP4, JUN, FOS,PTGS2, CTGF, VEGFA
Hypoxia-inducible miRNA and stimulator of
TGFβ-signaling pathways [135]
miR-24 Nanog, Oct-3/4, BimL, F1H1, HIF-1α, Snail,VEGFA Hypoxia-inducible miRNA [136]
Major tumor suppressor miRNAs in breast cancer
miR-497 Cyclin E1 Anti-proliferative and G1-S cell cycle arrest [59]
SMAD7 Anti-metastasis and anti-invasion [99]
CD274 Anti-metastasis, anti-tumorigenic and inhibitionof immune response or tumor immune escape [106]
VEGF, HIF-1α Anti-angiogenesis and anti-tumorigenic [138]
miR-16 Cyclin E1, E2F7 Anti-proliferative and G1–S cell cycle arrest,restores tamoxifen sensitivity [60,73]
miR-30c-2-3p Cyclin E1 Anti-proliferative and G1–S cell cycle arrest [61]
miR-483-3p Cyclin E1, p-NPAT, CDK2 Anti-proliferative and G1–S cell cycle arrest [62]
miR-143 ERK5, MAP3K7, Cyclin D1 Anti-proliferative [63]
miR-455 CDK14, Cyclin D1, p21 Anti-proliferative [64]
miR-424 CDK1, YAP, p-ERK1/2 Anti-proliferative and G2–M cell cycle arrest [65]
miR-543 ERK/MAPK Anti-proliferative, cell cycle arrest and apoptosis [66]
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Table 1. Cont.
MicroRNA Interacted/Correlated Gene(s) and Protein(s) Associated Events Reference
Major tumor suppressor miRNAs in breast cancer
miR-26a Cyclin D1, CDK4, CDK6, p21, p27, p53,RNF6/ERα/BCL-xL, E2F7, MYC, cyclin E2
Anti-proliferative, G1 cell cycle arrest and
restores sensitivity to tamoxifen and trastuzumab
treatment
[67,74,75]
miR-206 WBP2, p21, CDK4, cyclin D1 Anti-proliferative, cell cycle arrest and restoressensitivity to tamoxifen treatment [72]
miR-15a Cyclin E1, E2F7 Anti-proliferative and G1–S cell cycle arrest,restores tamoxifen sensitivity [73]
miR-30b Cyclin E2 Anti-proliferative, G1 cell cycle arrest andrestores sensitivity to trastuzumab treatment [75]
miR-365 GALNT4 Anti-proliferative and restores sensitivity toFluorouracil chemotherapeutic treatment [76]
miR-22 KRAS Anti-proliferative and restores sensitivity toPaclitaxel chemotherapeutic treatment [77]
miR-708 IKKβ, COX-2, c-MYC
Anti-proliferative and regulates cell cycle arrest
upon induction of glucocorticoid agonists, DEX
and ATA
[79]
miR-124a and
miR-26b SerpinB2 Anti-metastasis and anti-invasion [86]
miR-195 FASN, HMGCR, ACACA, CYP27B1
Anti-metastasis and anti-invasion by
underregulation in plasma of metastatic breast
cancer patients
[89]
CD274 Anti-metastasis, anti-tumorigenic and inhibitsimmune response or tumor immune escape [106]
miR-148a
WNT-1, β-catenin, MMP-7, TCF-4 Anti-metastasis and anti-invasion by regulatingWnt/β-catenin signaling pathway [93]
BCL-2, caspases Promotes apoptotic response and overcomeschemoresistance [116]
miR-340 c-MYC, CTNNB1, ROCK1
Anti-metastasis and anti-invasion by regulating
Wnt/β-catenin and Rho/Rho-associated kinase
(ROCK) signaling pathways
[94]
miR-34a TPD52, E-cadherin, TGF-β, N-cadherin Anti-metastasis and anti-invasion by regulatingEMT [95]
P53 Pro-apoptotic effect can be induced by kallistatin [119]
miR-138 E-cadherin, vimentin, N-cadherin, Snail Anti-metastasis and anti-invasion by regulatingEMT [96]
miR-494 PAK1, E-cadherin Anti-metastasis and anti-invasion [97]
miR-33b HMGA2, SALL4, Twist 1 Anti-metastasis and anti-invasion [98]
miR-421 MTA1 Anti-metastasis and anti-invasion [100]
miR-193a WT1 Anti-metastasis and anti-invasion [101]
miR-211-5p SETBP1 Anti-metastasis and anti-invasion [102]
miR-335 EphA4 Anti-metastasis and anti-invasion [103]
miR-133a LASP1 Anti-metastasis and anti-invasion [104]
miR-124 STAT3 Anti-metastasis and anti-invasion [105]
miR-204-5p PIK3CB
Anti-metastasis, anti-tumorigenic, restores
sensitivity towards PIK3CB inhibitors and
chemotherapeutic drugs (i.e., doxorubicin,
taxanes and bortezomib), and involved in tumor
immune microenvironment remodeling
[108]
miR-204 JAK2, BCL-2, survivin Promotion of apoptotic response [115]
miR-101 EYA1, jagged1, Hes1, Hey1, SOX2 Promotion of apoptotic response by negativelyregulating Notch pathway [117,118]
miR-296-5p and
miR-512-5p hTERT
Reduction of telomerase activity, impairment of
telomere maintenance and activation of
replicative senescence and apoptosis programs
[120]
miR-29b Akt3, VEGF, c-MYC Anti-angiogenesis and anti-tumorigenesis [137]
miR-140-5p VEGFA, CD31, Ki-67, MMP-9 Anti-angiogenesis and anti-tumorigenesis [139]
miR-126 VEGFA Anti-angiogenesis and anti-tumorigenesis [140]
miR-100 VEGF, mTOR/HIF-1α
Shuttling of miRNA enriched in MSC-derived
exosomes, anti-angiogenesis and
anti-tumorigenesis
[143]
The oncomiRs and tsmiRs that involved in the post-transcriptional regulation of biological
functions and hallmarks of breast cancer are summarized in Table 1 and Figure 3.
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4. MicroRNAs and Breast Cancer Progression
Benign breast disease, such as atypical hyperplasia (AH), is associated with an increased risk
of breast cancer [144]. It has been proposed that breast tumorigenesis is a multistep process which
begins slowly with the development of clonally derived mammary cells, leading to AH, which then
further develops into carcinoma in situ (CIS), and finally into invasive carcinoma [145]. Early detection
of cancer at the stage of AH hyperplasia is therefore timelier for surgical intervention and is likely
to improve patient survival rate. However, at present, there are no biomarkers that can accurately
diagnose AH [146].
An et al. examined whether serum miRNAs could serve as biomarkers for discriminating between
patients with AH or early-stage breast cancer patients compared with healthy patients or patients
with benign proliferative tumors. From the pool of analyzed miRNAs, only miR-24 and miR-103a
showed significant downregulation in AH and early-stage breast cancer. By contrast, a slight increase
was observed for these miRNAs in the serum of benign proliferative tumor patients compared with
healthy individuals. However, there was no significant relationship between either of these miRNAs
and TNM Classification of Malignant Tumors (TNM) staging or clinical molecular subtypes, even
though their regulation was slowly reduced with the progression of breast cancer (ductal carcinoma in
situ (DCIS), I, II). In addition, analyses employing gene ontology (GO) enrichment analysis and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways revealed that the candidate gene targets of
miR-24 and miR-103a were potentially involved in critical molecular signaling pathways of breast
tumorigenesis, such as gene expression regulation, apoptotic processes, and Wnt and Notch signaling
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pathways. Interestingly, the key proteins of miRNA biogenesis, such as Dicer 1, Ago1, and Ago4,
are also predicted target genes for miR-103a, suggesting a stem-loop feedback mechanism of regulation.
However, this research was limited by a small sample size and the lack of a detailed exploration of the
mechanisms behind this miRNA’s involvement in breast cancer progression [147].
Additionally, Stankevicins et al. performed a miRNA microarray-based global expression analysis
on a series of 21T cell line representing different stages of breast cancer. This analysis showed that only
miR-205-5p was markedly downregulated in the metastatic, invasive cell lines (21MT-1 and 21MT-2)
relative to the localized, non-proliferative cells (21PT and 21NT). The reduced expression of miR-205-5p
was also associated with advanced histopathological tumor grade and increased invasion rates in a
Boyden chamber cell migratory assay. Although not statically significant, transfection of metastatic
cells (21MT1 and 21MT2 cells) with miR-205-5p precursor resulted in reduced migratory potential,
whereas healthy and in situ cells (H16N2, 21PT and 21NT cells) transfected with miR-205-5p inhibitor
showed partial elevation in migration rate. miR-205-5p was also predicted to target genes responsible
for breast cancer invasiveness, including SOCS3, PTPRN2, and MMP3, and also genes associated with
EMT regulatory functions, such as TGFB1. Therefore, this work showed that miR-205-3p may serve as
a key player during progression of a tumor to an invasive, metastatic phenotype [148].
In summary of the above findings, dysregulation of miRNA expression appears to play a pivotal
role in the transition from non-proliferative cellular conditions to a cancerous state. Most of the published
research conducted into miRNAs in the context of breast cancer only considers established, late-stage
breast cancer. Given the potential of miRNAs as sensitive biomarkers for early-stage cancer such as
benign breast disease, in which disease prognosis is considerably more favorable, more research is
needed to investigate the regulatory impact of these molecules specifically in early-stage breast cancer.
5. MicroRNAs Act in Networks in Their Regulation of Breast Cancer
As discussed above, a single miRNA or miRNAs can critically regulate genes controlling various
pathobiological processes implicated in cancer. However, most of the studies discussed above focused
on the role of miRNA(s) solely as discrete entities, without considering the complex, interconnected
nature of the breast cancer ‘miRNome’. As any given miRNA is predicted to target up to thousands
of mRNA transcripts, it is a profound challenge to identify the miRNA or group of miRNAs that are
the most prominent regulators of breast cancer pathological processes. In fact, to date, there are no
clear miRNA expression profiles that are interlinked between various human cancers. As an example,
miR-498 can serve as a potential oncomiR in both breast cancer and prostate cancer by targeting the
tumor suppressor gene PTEN [149]. At the same time, miR-498 functions as a tsmiR in liver cancer by
targeting the oncogene ZEB2 [150]. In breast cancer cells, other oncomiRs, miR-1297 and miR-103b,
are also responsible for breast tumorigenesis by directly targeting PTEN [151,152], whereas miR-221
and miR-19a-3p also displayed potent oncogenic roles through negative regulation of PTEN in lung
and hepatocellular carcinoma, respectively [153,154]. Therefore, it is worthwhile to investigate or
refine the molecular co-relation in terms of miRNAs, their target genes, and the respective signaling
pathways in future studies for better prognostication, detection, and treatment of human cancers.
In addition, attention should also be given to discoveries that focus on the unique and novel miRNA
regulatory trends in breast pathobiology.
A study by De Anda-Jáuregui et al. identified a set of five miRNAs, miR-190b, miR-let-7i, miR-292-b,
miR-511, and miR-141 (also known as Commodore miRs; Cdre-miRs), that were non-redundant and
highly interconnected in regulating a large network of associated genes in breast cancer [155]. It was
found that miR-190b regulated a group of genes involved in dynein assembly, vitamin metabolism,
and mammary gland epithelial cell proliferation. Genes associated with melanocyte transport,
angiogenesis, and epithelial cell migration were regulated by miR-292-b; genes of motility, migration,
and extracellular matrix organization were controlled by miR-141; genes of cytokine production and cell
activation were under the regulation of miR-511; whereas gene neighbors related to adaptive immune
response and leukocyte cell–cell adhesion were under modulation by miR-let-7i. There was a lack of
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overlaps between the gene neighborhoods regulated by each Cdre-miR, but both miR-511 and miR-let-7i
Cdre-miRs were responsible for co-regulation of the innate immunity process. As each Cdre-miR is an
important control element of specific biological processes, their removal or alteration will lead to the
disconnection of a group of genes which then impair certain biological functionality [155].
The action of these non-redundant Cdre-miRs in the form of highly interconnected networks is
a property that is only found in the context of breast cancer. Interestingly, no Cdre-miR transcripts
have been identified in healthy breast tissue. Therefore, Cdre-miRs could potentially serve as novel
biomarkers in monitoring the transcriptional regulatory perturbations observed in breast cancer,
and even as attractive therapeutic targets [155].
6. Therapeutic Potential and Delivery Options of MicroRNAs in Breast Cancer
Owing to their small molecular size and ability to regulate the expression of genes associated
with the progression of various cancers, miRNAs have the potential to revolutionize breast cancer
therapeutics [156]. Potential miRNA-based breast cancer therapies are generally based on the
approaches of either silencing oncogenic miRNAs via miRNA inhibitors or restoring the functions of
tumor suppressor miRNAs via miRNA mimetics. Experimental studies of the potential therapeutic
utility of miRNA-focused approaches have, to date, generally employed in vitro techniques to quantify
their effects on mRNA and protein concentrations.
miRNA inhibition therapy can be used to restore the normal expression and function of the
target tumor suppressor genes by inhibition of the normally upregulated oncogenic miRNAs in
human breast cancers. miRNA antagonists or antagomirs are complementary single-stranded and
chemically modified oligonucleotides that can expropriate or competitively inhibit the endogenous
oncogenic miRNAs from being recognized and processed by RISC. This renders the inhibited
miRNAs no longer able to recognize or interact with their target tumor suppressor mRNAs [157].
Antagomirs such as 2′-O-methyl modified oligonucleotides, locked nucleic acid (LNA) anti-miRs, and
cholesterol-conjugated antagomirs are among the miRNA inhibitors that are widely used in miRNA
inhibition therapy [158]. In addition, there has also been interest in the therapeutic potential of miRNA
sponges which contain multiple artificial miRNA binding sites that can competitively bind and inhibit
specific miRNAs or clusters of miRNAs [159]. By contrast, miRNA masks can bind to the target mRNA
and selectively inhibit the interaction with the specific miRNA [160]. These masking nucleic acids can
precisely mask the mRNA from the endogenous miRNA and thus prevent its suppression.
In miRNA replacement therapy, the normal function of the tumor-suppressive miRNAs can be
re-established by replacing or substituting the downregulated miRNAs by employing miRNA-like
synthetic molecules known as miRNA mimics [157]. These miRNA mimics are small, chemically
modified 2′-O’-methoxy RNA duplexes that can be loaded into RISC, mimicking the function of
endogenous miRNAs by inhibiting the target mRNAs that are commonly oncogenic [157].
In general, miRNA modulators have low stability; the naked RNAs tend to be degraded by
nucleases and removed from the body by renal excretion [161]. Thus, the specific, efficient, and safe
delivery of miRNA modulators to the tumor sites is crucial for the success of miRNA-based cancer
therapeutic strategies. Effective miRNA delivery has been shown by employing various viral vectors,
such as lentivirus, retrovirus, adenovirus, and adeno-associated virus (AAV), expressing miRNA
antagonists or mimics [162]. In addition, nanostructured lipid carriers, such as liposomes consisting of
lipid bilayers, have also been successfully employed; these encapsulate the miRNA antagonists or
mimics, protecting them from nuclease degradation and increasing the stability of their delivery into
the cells [163]. Nanoparticles such as altered polyethylene glycol (PEG), inorganic nanoparticles (iron,
gold, carbon, silica), and nanoparticles with targeting molecules such as ligands, peptides, or antibodies
can also be used for effective miRNA delivery [156]. Furthermore, polymer-based methods also have
potential due to their biodegradability and high electrostatic affinity for cellular membranes [164].
miRNA delivery has also been achieved using synthetic polyethylenimine (PEI), poly (lactic-co-glycolic
acid) (PLGA), and other natural cationic polymers such as chitosan and atelocollagen [165].
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CRISPR (clustered regularly interspaced short palindromic repeats)-Cas 9 (CRISPR-associated
protein 9) is a newly emergent genome editing approach that has gained widespread attention as a
technique for full and permanent gene knockout [166]. CRISPR-Cas 9 has been used for editing of
protein-coding genes in breast cancer, including HER2 [167] and MIEN1 [168]. However, editing of
non-protein coding RNA genes (including miRNAs) using this approach has received relatively little
attention. Most of the currently published strategies of miRNA replacement have relied on transient
transfection of miRNA inhibitors or antagomiRs into the cells [169], only promoting their expression
for a finite period of time without integration into the cell genome [170]. Additionally, it has been
suggested that the transfected material is likely to be degraded by nucleases or diluted following cell
division [170]. However, in a recent study by Hannafon et al., CRISPR-Cas9 deletion of miR-23b and
miR-27b was performed in order to study their regulation of breast cancer cells [171]. The genomic
knockdown of miR-23b/27b resulted in reduced cell proliferation rate, formation of fewer cell colonies,
and the attenuation of anchorage-independent growth in vitro. Furthermore, the growth rate and
tumor volume of xenografts from miR-23b/27b knockout mice was dramatically reduced compared to
control mice treated with empty vectors. These data therefore suggest that editing of genes encoding
endogenous miRNAs is a potentially revolutionary therapeutic approach for breast cancer.
7. Conclusions
There is a vast and growing literature that firmly supports the involvement of miRNAs in cancers
such as breast cancer. It is becoming more widely acknowledged that these molecules play important
roles in regulating gene expression in order to achieve homeostasis, and that dysregulation of their
activity can lead to adverse consequences in a wide range of disease pathways. There is therefore a great
potential for miRNA-based therapeutics to serve as highly specific approaches or targeted therapies for
breast cancer treatment. This potential is evidenced in in vitro studies, which show that miRNA-based
techniques can modulate the expression of target genes in a highly specific and effective way. However,
there are a number of challenges to overcome in order to successfully translate these promising
laboratory results into efficacious therapies in clinical practice. These factors include the development
of more efficient delivery options, the issue of degradation or instability, potential off-target effects,
and the long-term safety of these agents in vivo. Furthermore, the underlying mechanisms that govern
the interactional networks between miRNAs and the human genome, transcriptome and proteome
have to be clearly understood before their effective transition into medical or pharmaceutical settings.
It is therefore important that the wider consequences of candidate miRNA-based therapies are studied
in vivo within a complex biological system, using multiomics approaches, for example. Additionally,
among the dysregulated miRNAs in breast cancer specifically, it is important to determine the most
representative miRNA or groups of mRNAs at each stage of the disease; this will help to identify
and prioritize the most promising treatment targets, with emphasis on developing strategies to detect
and treat breast cancer earlier. In conclusion, the advancement in miRNA-based therapeutics has the
potential to revolutionize and personalize breast cancer treatment. A more in-depth knowledge of
the mechanisms of action and the wider biological consequences of miRNA-based therapies is first
required, but these should not be considered insurmountable barriers to combatting this common and
devastating disease.
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